FDA expands indication for Amgen psoriasis drug

Amgen has received approval for its plan to expand the usage of psoriasis drug Otezla.


US healthcare professionals can now prescribe Otezla no matter how severe a patient's psoriasis is.

The FDA approved an indication expansion for the tablet treatment, which Amgen acquired from Celgene in 2019 for a sum of DKK 90bn (USD 13.7bn). At the time, Celgene was merging with Bristol Myers Squibb, and was instructed by the US Competition Authotities to sell the treatment.

The expanded approval means that Otezla can be used in cases of mild, moderate and severe plaque psoriasis.

During the third quarter of 2021 alone, Otezla generated sales of USD 609m.

Former Leo Pharma candidate heads into big study as FDA fast-tracks assessment

Express Scripts to cover psoriasis cream from MC2 Therapeutics

Eli Lilly submits tirzepatide for approval in US and EU 

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs